Stay updated on BCD-020 vs MabThera in Rheumatoid Arthritis Clinical Trial

Sign up to get notified when there's something new on the BCD-020 vs MabThera in Rheumatoid Arthritis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the BCD-020 vs MabThera in Rheumatoid Arthritis Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a significant update in the study record related to the safety and efficacy evaluation of BCD-020 and MabThera in patients with rheumatoid arthritis who had an inadequate response or intolerance to other DMARDs, including TNF inhibitor therapies.
    Difference
    0.1%
    Check dated 2024-06-06T14:48:46.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participation in the study, specifying age range, health conditions, and prior treatments required for participants. Previously, no information was provided regarding participation criteria.
    Difference
    31%
    Check dated 2024-05-22T21:30:01.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:52:49.000Z thumbnail image

Stay in the know with updates to BCD-020 vs MabThera in Rheumatoid Arthritis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the BCD-020 vs MabThera in Rheumatoid Arthritis Clinical Trial page.